[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368684-105":59,"doc-detail-368684-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","comprehensive-pan-cancer-analysis-identifies-igfl1-as-an-oncogenic-biomarker-and-immunotherapeutic-target-with-experimental-validation-in-bladder-cancer","Comprehensive Pan-Cancer Analysis Identifies IGFL1 as an Oncogenic Biomarker and Immunotherapeutic Target with Experimental Validation in Bladder Cancer","","This research investigates IGFL1 as a cancer-associated insulin growth factor-like family member, focusing on its expression patterns, prognostic value, and immunological relevance across cancers, with experimental validation in bladder cancer (BLCA). Pan-cancer analyses using TCGA, GTEx, and TIMER2.0 evaluate expression, survival links, immune subtypes, immune infiltration, and tumor genomic features, plus drug sensitivity data. In BLCA, IGFL1 is upregulated and functionally drives proliferation, migration, EMT, and immune modulation via JAK2/STAT3.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-pan-cancer-analysis-identifies-igfl1-as-an-oncogenic-biomarker-and-immunotherapeutic-target-with-experimental-validation-in-bladder-cancer/368684/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-pan-cancer-analysis-identifies-igfl1-as-an-oncogenic-biomarker-and-immunotherapeutic-target-with-experimental-validation-in-bladder-cancer/368684.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of this study regarding IGFL1?","Question",{"text":112,"@type":113},"To determine IGFL1 expression patterns across cancers and evaluate its prognostic and immunological significance, then validate its role experimentally in bladder cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which datasets and analyses were used to study IGFL1 in pan-cancer cohorts?",{"text":117,"@type":113},"TCGA, GTEx, and TIMER2.0 were used to assess IGFL1 expression and correlations with prognosis, immune subtypes, immune infiltration, tumor genomic features, and drug sensitivity.",{"name":119,"@type":110,"acceptedAnswer":120},"How does IGFL1 affect bladder cancer cells and tumors in this study?",{"text":121,"@type":113},"IGFL1 knockdown reduced proliferation, migration, and EMT-related protein expression, while overexpression had opposite effects; in vivo, IGFL1 silencing suppressed xenograft growth and increased apoptosis and T-cell infiltration.",{"name":123,"@type":110,"acceptedAnswer":124},"Through which signaling pathway are IGFL1’s effects proposed to be mediated?",{"text":125,"@type":113},"Mechanistic analysis suggests IGFL1 signals through the JAK2/STAT3 pathway.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368684,1790198193,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":31,"preview_page_count":14,"preview_urls":148},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","International Journal of General Medicine  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nComprehensive Pan-Cancer Analysis Identifies IGFL1 as an Oncogenic Biomarker and Immunotherapeutic Target with Experimental Validation in Bladder Cancer  \nZongjian Liang 1 , *, Yu An2 , *, Jie He2 , Zhiqiang Zhu 1 , Kehua Jiang 3 , Kun Chen 4 , Fa Sun 1  \n1Department of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, People’s Republic of China; 2NHC Key Laboratory of Pulmonary Immune-Related Diseases, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, People’s Republic of China; 3Department of Urology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, People’s Republic of China; 4Department of Medical Genetics, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Kun Chen, Department of Medical Genetics, Guizhou Provincial People’s Hospital, 83 Zhongshan East Road, Guiyang, Guizhou, 550081, People’s Republic of China, [Email 44844956@qq.com](Email 44844956@qq.com); Fa Sun, Department of Urology, the Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, Guizhou, 550081, People’s Republic of China, Email [sfgmc@sina.com](sfgmc@sina.com)  \n\n| Background: IGFL1, a member of the insulin growth factor-like family, plays a potential role in tumorigenesis. This study aimed to investigate IGFL1 expression and its prognostic and immunological significance across cancers, with experimental validation in bladder cancer (BLCA) .\u003Cbr>Methods: Data from TCGA, GTEx, and TIMER2.0 were analyzed to assess IGFL1 expression across cancers and its associations with prognosis, immune subtypes, immune infiltration, and tumor-related genomic features. Drug sensitivity data were also evaluated. Given BLCA’s high mutation burden, limited treatment options, and strong IGFL1 dysregulation observed in pan-cancer analysis, we selected it for experimental validation. In vitro and in vivo experiments were conducted to validate the oncogenic role of IGFL1 in BLCA and explore its underlying mechanisms.\u003Cbr>Results: IGFL1 was significantly overexpressed in 10 tumor types and associated with advanced stage and grade in BLCA. High IGFL1 expression correlated with poor prognosis in OV, SARC, HNSC, PAAD, UCEC, KIRC, and BLCA. IGFL1 expression was linked to features of the tumor microenvironment in several cancers. In BLCA tissues, IGFL1 levels were markedly elevated. Knockdown of IGFL1 in 5637 and ScaBER cells reduced proliferation, migration, and epithelial–mesenchymal transition (EMT) -related protein expression; overexpression had the opposite effect. In vivo, IGFL1 silencing suppressed xenograft tumor growth, decreased Ki67 expression, increased apoptosis, and enhanced CD4⁺ and CD8⁺ T-cell infiltration. Mechanistic analysis suggested that IGFL1’s effects are mediated through the JAK2/STAT3 signaling pathway.\u003Cbr>Conclusion: IGFL1 promotes tumor progression and immune modulation in multiple cancers, particularly in BLCA. Its oncogenicand immunosuppressive roles, mediated through the JAK2/STAT3 axis, support its potential as a prognostic biomarker and therapeutic target.\u003Cbr>Keywords: IGFL1, pan-cancer, bladder cancer, tumor immunology, tumorigenesis |\n| --- |\n| Introduction\u003Cbr>Cancer remains the primary cause of death globally, imposing a huge health and economic burden on nations each year.1 Tumorigenesis is a multifaceted biological process that engages numerous signaling pathways and key genes, among which the tumor microenvironment (TME) plays a pivotal role.2,3 With the advancement of resource sharing and public databases, comprehensive pan-cancer analyses of genes have become possible, providing valuable insights for identifying new targets for immunotherapy. |\n\nReceived: 7 February 2025  \nAccepted: 10 July 2025  \nPublished: 15 July 2025  \nInternational Journal of General Medicine 2025:18 3881–3900 3881","cbCaidO49RjpKOCr","https://ap.wps.com/l/cbCaidO49RjpKOCr","pdf",17837712,"English","# Background\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What was the main goal of this study regarding IGFL1?\",\"answer\":\"To determine IGFL1 expression patterns across cancers and evaluate its prognostic and immunological significance, then validate its role experimentally in bladder cancer.\"},{\"question\":\"Which datasets and analyses were used to study IGFL1 in pan-cancer cohorts?\",\"answer\":\"TCGA, GTEx, and TIMER2.0 were used to assess IGFL1 expression and correlations with prognosis, immune subtypes, immune infiltration, tumor genomic features, and drug sensitivity.\"},{\"question\":\"How does IGFL1 affect bladder cancer cells and tumors in this study?\",\"answer\":\"IGFL1 knockdown reduced proliferation, migration, and EMT-related protein expression, while overexpression had opposite effects; in vivo, IGFL1 silencing suppressed xenograft growth and increased apoptosis and T-cell infiltration.\"},{\"question\":\"Through which signaling pathway are IGFL1’s effects proposed to be mediated?\",\"answer\":\"Mechanistic analysis suggests IGFL1 signals through the JAK2/STAT3 pathway.\"}]","Comprehensive Pan-Cancer Analysis Identifies IGFL1 as an Oncogenic Biomarker and Immunotherapeutic Target with Experimental Validation in Bladder Cancer | PDF",1790178045,[149,153],{"page_no":8,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/6e4a879287ba2d02699e4747d061de8c.webp",983,1272,{"page_no":14,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/4a7f7b4b0fe84caa64e191be891f372d.webp",982,1270]